Specialty Pharmacy

Researchers showed that treating multiple myeloma cells with gamma-secretase inhibitors allowed CAR T-cells to more accurately treat cancer tumors.

It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how Specialty Pharmacists can drive the data standardization conversation during the NASP Annual Meeting in Washington, DC.

The application is based on results from the phase II KEYNOTE-057 trial, which found that pembrolizumab has encouraging activity in patients with high-risk, BCG-unresponsive CIS with or without papillary tumors.

Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.

Top news of the day from across the health care landscape.

Five-day adjuvant IVIG therapy found to significantly reduce viral load in an immunocompromised patient with severe varicella.

Researchers have identified a channel in nerve cells that may serve as a new approach to targeting Parkinson disease.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss during the future of data in Specialty Pharmacy at the NASP Annual Meeting in Washington, DC.

Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss value-based care and whether or not it poses challenge to data standardization in specialty pharmacy during the NASP Annual Meeting in Washington, DC.

The findings suggest that biologics can be used for those with elderly-onset rheumatoid arthritis (RA) as effectively as for those with young-onset RA.

Top news of the day from across the health care landscape.

The phase 3b/4 SPIRIT head-to-head study evaluated ixekizumab (Taltz) versus adalimumab (Humira) in psoriatic arthritis.

The FDA approved elexacaftor/tezacaftor/ivacaftor (Trikafta) earlier this month based on the results of a phase 3 clinical trial.

Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.

The FDA approved voxelotor (Oxbryta, Global Blood Therapeutics) tablets for the treatment of sickle cell disease in patients 12 years of age and older.

Top news of the day from across the health care landscape.

The case study included a 45-year-old man diagnosed with stage 3 multiple myeloma who was treated with bortezomib and dexamethasone.

If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how pharmacy schools can better prepare students for Specialty Pharmacy during the NASP Annual Meeting in Washington, DC.

The study evaluated the safety and efficacy of a live, attenuated zoster vaccine patients receiving tumor necrosis factor inhibitor therapies for various indications.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The FDA has approved cenobamate tablets (XCOPRI, SK Life Sciences) for treatment of partial-onset seizures in adults.

Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.

The 48-week phase 4 study showed that tocilizumab was more effective than rituximab in patients with rheumatoid arthritis with low B cell levels in synovial tissue.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the benefits of attending NASP during the NASP Annual Meeting in Washington, DC.